NCT02912169

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease

Withdrawn Phase 1, PHASE2 Last updated 24 November 2017

What this trial tests

Phase 1, PHASE2 trial testing Liposuction under local anesthesia in Alzheimer's Disease. Withdrawn.

Timeline

1 November 2015

Primary endpoint
15 November 2017

15 November 2017

Quick facts

Lead sponsor	Ageless Regenerative Institute
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 November 2015
Primary completion	15 November 2017
Estimated completion	15 November 2017
Sites	1 location across United States

Drugs / interventions tested

• Liposuction under local anesthesia
• Infusion of AD-SVF via IV and Intranasal — full drug profile →

Conditions studied

• Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

Ageless Regenerative Institute

Who can join

Adults 55 to 85, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with Alzheimer's Disease and clinical outcomes?

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Alzheimer's disease drug development pipeline: 2017.
   Cummings J, Lee G, Mortsdorf T, Ritter A, et al · · 2017 · cited 258× · PMID 29067343 · DOI 10.1016/j.trci.2017.05.002
2. Alzheimer's disease, dementia, and stem cell therapy.
   Duncan T, Valenzuela M. · · 2017 · cited 212× · PMID 28494803 · DOI 10.1186/s13287-017-0567-5
3. The Link between Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammation in the Pathophysiology of Alzheimer's Disease: Therapeutic Implications and Future Perspectives.
   Jurcău MC, Andronie-Cioara FL, Jurcău A, Marcu F, et al · · 2022 · cited 119× · PMID 36358538 · DOI 10.3390/antiox11112167
4. Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease.
   Kwak KA, Lee SP, Yang JY, Park YS. · · 2018 · cited 26× · PMID 29686714 · DOI 10.1155/2018/6392986
5. Recent Advances: Decoding Alzheimer's Disease With Stem Cells.
   Fang Y, Gao T, Zhang B, Pu J. · · 2018 · cited 24× · PMID 29623038 · DOI 10.3389/fnagi.2018.00077
6. Molecular Pathogenesis and Interventional Strategies for Alzheimer's Disease: Promises and Pitfalls.
   Bhute S, Sarmah D, Datta A, Rane P, et al · · 2020 · cited 21× · PMID 32566913 · DOI 10.1021/acsptsci.9b00104
7. The Nasal-Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases.
   Qiu Y, Huang S, Peng L, Yang L, et al · · 2025 · cited 18× · PMID 40487748 · DOI 10.1002/mco2.70213
8. Cell primitive-based biomimetic nanomaterials for Alzheimer's disease targeting and therapy.
   Yin T, Liu Y, He B, Gong B, et al · · 2023 · cited 11× · PMID 37706205 · DOI 10.1016/j.mtbio.2023.100789